CDK5 and neoplasm: Indeed, several pharmacological CDK5 inhibitors have been undergoing preclinical/clinical trials for possible anticancer applications and are yielding promising responses.[39] In the current study, we first found the existence of CDK5 activation in tumor tissues of TNBC patients at different stages and then established the primary positive correlation between aberrant CDK5 activation and TNBC progression.